Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited
Key Takeaways
- Mounjaro is a dual GLP-1 and GIP receptor agonist, not a pure GLP-1 medication
- Its active ingredient is tirzepatide, manufactured by Eli Lilly and approved in May 2022
- Mounjaro is approved for type 2 diabetes; Zepbound (same molecule) is approved for obesity
- Tirzepatide produces larger weight loss and stronger glycemic effects than semaglutide in head-to-head trials
- The "yes-and-no" answer reflects that tirzepatide activates the GLP-1 receptor as part of its mechanism but is not exclusively a GLP-1 drug
Direct answer
Mounjaro is best described as a dual incretin receptor agonist. Its active ingredient, tirzepatide, activates the GLP-1 receptor and the GIP receptor at the same time. In a strict pharmacology sense, Mounjaro is not a pure GLP-1 medication. In everyday clinical conversation, it is often grouped with the GLP-1 class because the patient experience, side-effect profile, and clinical positioning overlap heavily with drugs like Ozempic and Wegovy.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The honest yes-and-no answer
- What tirzepatide is at the molecular level
- The GIP receptor and why adding it matters
- The head-to-head data against Ozempic
- Mounjaro vs Zepbound: same molecule, different label
- How dual agonism changes the side-effect picture
- The approval pathway and SURPASS/SURMOUNT trials
- Where Mounjaro sits in current treatment algorithms
- The compounding story for tirzepatide
- Contrary view: maybe the GIP component is overhyped
- Decision framework
- FAQ
- Sources
The honest yes-and-no answer
If someone asks whether Mounjaro is a GLP-1, the cleanest accurate answer has two parts.
Yes, in the sense that Mounjaro activates the GLP-1 receptor. The GLP-1 component of its mechanism is real and substantial. The patient experience overlaps with Ozempic and Wegovy: weekly subcutaneous injection, gradual dose titration, similar nausea profile, similar weight-loss trajectory. Most clinicians will say "yes, Mounjaro is a GLP-1" and proceed.
No, in the sense that pharmacologists classify Mounjaro as a dual GLP-1 and GIP receptor agonist (sometimes called a "twincretin"). The molecule was engineered specifically to activate two receptors. The GIP receptor component is part of why tirzepatide produces stronger effects than pure GLP-1 RAs like semaglutide. Saying Mounjaro is "just a GLP-1" undersells what the drug actually does.
The middle position works for most situations: Mounjaro is in the incretin-agonist family. It shares mechanism, side effects, and clinical positioning with GLP-1 RAs. It is technically a dual agonist, not a pure GLP-1. Both can be true at the same time.
What tirzepatide is at the molecular level
Tirzepatide is a 39 amino acid synthetic peptide. The sequence is engineered to bind both the GLP-1 receptor and the GIP receptor with high affinity. The molecule also carries a fatty acid side chain (a C20 fatty diacid) attached via a linker, similar in concept to the modification used in semaglutide and liraglutide.
The fatty acid chain has two effects. It binds to albumin in the blood, which extends the molecule's circulation time. And it resists DPP-4, the enzyme that breaks down native incretin hormones within minutes. Together these modifications give tirzepatide a half-life of about 5 days, allowing weekly subcutaneous dosing.
The receptor binding profile is the unusual part. Native human GIP binds the GIP receptor; native human GLP-1 binds the GLP-1 receptor. Tirzepatide is one of the first widely marketed drugs that intentionally activates both at once. Its affinity for GIP is roughly equivalent to native GIP, while its affinity for GLP-1 is somewhat lower than native GLP-1. The resulting effect is described as "GIP-leaning" in some pharmacology papers, although the clinical relevance of that asymmetry remains debated.
The GIP receptor and why adding it matters
GIP, glucose-dependent insulinotropic polypeptide, was actually discovered before GLP-1. It is released by K-cells in the upper small intestine (primarily the duodenum and proximal jejunum) in response to fat and carbohydrate intake. Like GLP-1, it stimulates insulin release in a glucose-dependent manner.
GIP fell out of favor as a drug target for decades because patients with type 2 diabetes appeared to have reduced GIP responsiveness. The receptor seemed broken in the very people the drug was supposed to help. Adding a GIP-active drug seemed like a dead end.
The reframe came in the 2010s. Investigators showed that GIP signaling, while blunted at baseline in type 2 diabetes, could be restored when glucose control improved. They also found GIP receptors in adipose tissue, the central nervous system, and other locations relevant to metabolism. The dual-agonist concept began to look attractive.
Tirzepatide demonstrated the concept's value. The clinical results from SURPASS and SURMOUNT trials were larger than what semaglutide had achieved at comparable doses. Whether the additional benefit comes specifically from GIP receptor activation, from greater overall receptor engagement, or from some other property of the molecule remains a research question. The clinical outcomes, however, are unambiguous.
The head-to-head data against Ozempic
SURPASS-2 (Frias et al., New England Journal of Medicine 2021) compared tirzepatide and semaglutide directly in adults with type 2 diabetes. The design used three tirzepatide doses (5 mg, 10 mg, 15 mg weekly) against semaglutide 1.0 mg weekly. The primary endpoint was HbA1c reduction at 40 weeks.
| Treatment | HbA1c reduction | Weight loss | Patients reaching A1c <7.0% |
|---|---|---|---|
| Tirzepatide 5 mg | 2.01% | 7.6 kg | 82% |
| Tirzepatide 10 mg | 2.24% | 9.3 kg | 85% |
| Tirzepatide 15 mg | 2.30% | 11.2 kg | 86% |
| Semaglutide 1.0 mg | 1.86% | 5.7 kg | 79% |
The differences favored tirzepatide at every dose. The largest gap, at the 15 mg dose, was about 0.45 percent more HbA1c reduction and roughly twice the weight loss.
For weight-management context, SURMOUNT-1 (Jastreboff et al., New England Journal of Medicine 2022) tested tirzepatide in adults with obesity without diabetes. Mean weight loss at 72 weeks was 22.5 percent of body weight on the 15 mg dose, compared with about 14.9 percent for semaglutide 2.4 mg in STEP 1 (different trial, similar population). The cross-trial comparison is not perfect, but the magnitude favors tirzepatide.
SURMOUNT-5, a direct head-to-head between tirzepatide and semaglutide for obesity, reinforced the gap.
Mounjaro vs Zepbound: same molecule, different label
Eli Lilly markets tirzepatide under two brand names: Mounjaro for type 2 diabetes, Zepbound for chronic weight management. The molecules are identical. The pens look different. The products are differentiated by approved indication, titration schedule, and insurance coverage.
Mounjaro doses for diabetes: 2.5 mg starting (titration only), then 5, 7.5, 10, 12.5, and 15 mg weekly. Maintenance is generally 5 to 15 mg, individualized by glycemic response.
Zepbound doses for obesity: 2.5 mg starting (titration only), then 5, 7.5, 10, 12.5, and 15 mg weekly. The titration schedule is similar, but the weight-management labeling emphasizes ongoing chronic use rather than glycemic targeting.
The parallel structure mirrors Novo Nordisk's split between Ozempic (semaglutide for diabetes) and Wegovy (semaglutide for obesity). The pattern reflects both regulatory pathways (separate trials for separate indications) and commercial differentiation.
How dual agonism changes the side-effect picture
The side-effect profile of tirzepatide overlaps heavily with pure GLP-1 RAs. The most common adverse events in trials were:
- Nausea (about 18 to 24 percent of patients, dose-dependent)
- Diarrhea (about 12 to 17 percent)
- Vomiting (about 5 to 13 percent, dose-dependent)
- Constipation (about 6 to 9 percent)
- Decreased appetite (often reported as desired effect)
The pattern is similar to semaglutide, but with somewhat higher rates of GI events at the highest dose. The SURPASS-2 discontinuation rate due to adverse events was about 4.9 to 8.7 percent across tirzepatide doses, compared with 4.1 percent for semaglutide 1.0 mg. Most discontinuations were related to GI tolerability.
Like other incretin agonists, tirzepatide carries a boxed warning for medullary thyroid carcinoma, based on rodent data. It is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Other warnings include acute pancreatitis, acute gallbladder disease, severe gastrointestinal adverse reactions, acute kidney injury (secondary to dehydration), and hypoglycemia when combined with insulin or sulfonylureas.
Whether the GIP component contributes any additional safety signal is not clear from the available data. The trials did not show distinct GIP-related effects beyond what pure GLP-1 RAs produce.
The approval pathway and SURPASS/SURMOUNT trials
The FDA approved Mounjaro on May 13, 2022, for adults with type 2 diabetes. The approval rested on the SURPASS clinical trial program, which included SURPASS-1 (monotherapy), SURPASS-2 (vs semaglutide), SURPASS-3 (vs insulin degludec), SURPASS-4 (vs insulin glargine in high-CV-risk patients), and SURPASS-5 (add-on to insulin glargine).
Across the program, tirzepatide produced superior HbA1c reduction and weight loss compared with active comparators and placebo. The data supported approval at all three maintenance doses (5, 10, 15 mg).
Zepbound was approved for chronic weight management on November 8, 2023, based on the SURMOUNT clinical trial program. SURMOUNT-1 in adults with obesity, SURMOUNT-2 in adults with obesity and type 2 diabetes, SURMOUNT-3 with intensive lifestyle intervention, and SURMOUNT-4 examining weight maintenance after withdrawal. The combined data supported the obesity indication.
An expanded indication for cardiovascular risk reduction is under regulatory review based on SURPASS-CVOT data, which reported in 2024 and 2025. As of May 2026, the cardiovascular labeling for tirzepatide is not yet finalized.
Where Mounjaro sits in current treatment algorithms
The American Diabetes Association's 2025 Standards of Medical Care recommend GLP-1 RAs and dual incretin agonists as preferred second-line therapy after metformin in type 2 diabetes, particularly when weight loss is a treatment goal. Tirzepatide is recommended for its strong glycemic and weight-loss effects.
In obesity management, the AACE/ACE guidelines and the Obesity Society treatment recommendations place tirzepatide alongside semaglutide as first-line pharmacotherapy for chronic weight management in appropriate patients.
The practical positioning is that tirzepatide is now used in patients who would have received semaglutide a few years ago. The decision often comes down to insurance coverage, prior authorization requirements, and patient tolerability rather than clinical preference between the two.
The compounding story for tirzepatide
Tirzepatide was placed on the FDA drug shortage list in December 2022 due to manufacturing capacity. The shortage persisted through October 2024, when the FDA declared it resolved. During the shortage, 503A compounding pharmacies prepared compounded tirzepatide under specific FDA guidance.
After the shortage resolution, compounding under shortage rules ended. The FDA gave compounders a wind-down period and reinforced that compounded tirzepatide is not FDA-approved and is not equivalent to Mounjaro or Zepbound.
Compounded tirzepatide still exists through 503A personalized prescribing for specific patient needs, but the volume has shrunk significantly since 2024. Where it exists, it is a different product from Mounjaro: same molecule (tirzepatide), different manufacturing pathway, no FDA review of the specific preparation.
Contrary view: maybe the GIP component is overhyped
The dominant narrative attributes tirzepatide's superiority to the GIP component. There are reasonable arguments to challenge this.
First, dose comparisons in SURPASS-2 are not equivalent. Tirzepatide 15 mg was compared against semaglutide 1.0 mg. The higher-dose tirzepatide arm received a much larger absolute peptide quantity. Whether that drives the difference, rather than GIP per se, is hard to isolate.
Second, semaglutide at higher doses (the 2.4 mg dose used in Wegovy) approaches tirzepatide's weight loss more closely than the 1.0 mg comparator. Some authors argue that dose, not receptor profile, explains a large share of the difference.
Third, isolated GIP receptor agonists have not consistently produced weight loss in early-phase trials. If GIP alone were the secret, you would expect GIP agonists to work standalone. They mostly do not.
Fourth, GIP receptor antagonist drugs in development (which oppose GIP) have also shown weight-loss potential in early studies. This is paradoxical if GIP agonism drives weight loss. One hypothesis is that chronic GIP receptor stimulation eventually desensitizes the receptor, functioning more like antagonism. The biology is still being worked out.
The counterargument is that the dual agonism, whatever the exact mechanism, produces measurable clinical benefit. Patients on tirzepatide reliably lose more weight than patients on semaglutide. Whether the underlying biology is GIP-driven, dose-driven, or some other property does not change the bedside fact.
The reasonable position: dual agonism appears to matter clinically, but the specific role of GIP remains an active research question, not settled science.
Decision framework
If you have type 2 diabetes and your provider is choosing between Ozempic and Mounjaro:
- Mounjaro generally produces stronger glycemic and weight effects in head-to-head data.
- Side-effect rates are similar, with somewhat higher GI events at the top of the dose range.
- Insurance coverage and prior authorization may drive the practical decision.
If you want to lose weight without diabetes:
- Zepbound is the FDA-approved tirzepatide product for obesity. Mounjaro for weight loss is off-label.
- Zepbound vs Wegovy is a real clinical decision. Discuss with your provider.
If you are comparing classes in general:
- Mounjaro is a dual GLP-1/GIP agonist, technically distinct from pure GLP-1 RAs.
- The class boundary matters for understanding mechanism but rarely for daily prescribing decisions.
If you are considering compounded tirzepatide:
- Compounded tirzepatide is not Mounjaro and not Zepbound. It is a separate, non-FDA-approved product.
- Source quality matters. Verify the pharmacy is state-licensed and operates under 503A rules.
- Discuss with your provider whether compounded therapy fits your situation.
FAQ
Is Mounjaro a GLP-1? Mounjaro activates the GLP-1 receptor but is not a pure GLP-1 RA. It is a dual GLP-1 and GIP receptor agonist. Yes in the casual sense; technically a separate class in the precise sense.
What is the difference between Mounjaro and Ozempic? Mounjaro contains tirzepatide (dual GLP-1/GIP agonist) from Eli Lilly. Ozempic contains semaglutide (pure GLP-1 agonist) from Novo Nordisk. Tirzepatide produces larger glycemic and weight effects in head-to-head trials.
What is GIP and why does it matter? GIP is the second major incretin hormone, released by the upper small intestine after meals. It stimulates insulin release. Tirzepatide activates the GIP receptor in addition to the GLP-1 receptor, which appears to enhance the clinical effect.
Is Mounjaro stronger than Ozempic? In SURPASS-2, tirzepatide produced larger reductions in HbA1c and body weight than semaglutide at the doses tested. Individual responses vary.
Is Mounjaro approved for weight loss? No. Mounjaro is approved only for type 2 diabetes. The tirzepatide product for obesity is Zepbound.
Who makes Mounjaro? Eli Lilly and Company. Lilly also makes Zepbound (tirzepatide for obesity) and Trulicity (dulaglutide, a pure GLP-1 RA).
When was Mounjaro approved? May 13, 2022, for type 2 diabetes. Zepbound was approved on November 8, 2023, for chronic weight management.
Can I take Mounjaro for weight loss? Off-label only. The FDA-approved tirzepatide for weight loss is Zepbound, the same molecule under a different brand and labeled indication.
Is Mounjaro the same as Zepbound? Same active ingredient (tirzepatide). Different brand, different approved indication. The molecules are identical; the products are differentiated for labeling and reimbursement.
Does Mounjaro work if I'm not diabetic? The weight-loss effect occurs regardless of diabetes status, as shown in the SURMOUNT trials (which enrolled patients without diabetes). The relevant FDA-approved product for non-diabetic patients is Zepbound, not Mounjaro.
Is compounded tirzepatide the same as Mounjaro? No. Compounded tirzepatide is not FDA-approved. It uses the same active ingredient but is prepared by 503A pharmacies under individual prescriptions, with no FDA review of the specific preparation.
Will dual agonists replace pure GLP-1 RAs? Likely partially. Dual agonists produce larger effects but are not always available or affordable. Pure GLP-1 RAs remain important for patients with cardiovascular indications already supported by SUSTAIN-6 and SELECT, and for cost or supply reasons.
Sources
- FDA Prescribing Information. Mounjaro (tirzepatide). Updated 2024.
- Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
- Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA. 2024.
- Coskun T et al. LY3298176, a Novel Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus. Molecular Metabolism. 2018.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
- Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1). Lancet. 2021.
- Ludvik B et al. Once-Weekly Tirzepatide versus Once-Daily Insulin Degludec as Add-On to Metformin (SURPASS-3). Lancet. 2021.
- Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control (SURPASS-5). JAMA. 2022.
- FDA Drug Shortages Database. Tirzepatide Injection. 2022-2024.
- American Diabetes Association. Standards of Medical Care in Diabetes. 2025.
- Garvey WT et al. AACE/ACE Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
Footer disclaimers
Platform Disclaimer. FormBlends is a telehealth platform connecting patients with independent licensed providers and licensed U.S. pharmacies. We are not a pharmacy or medical practice. Prescription decisions are made by treating providers based on their independent clinical judgment.
Compounded Medication Notice. Compounded tirzepatide is distinct from Mounjaro and Zepbound. It is prepared by 503A compounding pharmacies in response to individual prescriptions and is not FDA-approved. The FDA has not reviewed compounded preparations for safety, purity, potency, or stability.
Results Disclaimer. Clinical trial averages reflect controlled study conditions and may differ from individual real-world results. Outcomes depend on adherence, dose, dietary patterns, exercise habits, baseline weight, and individual response to the medication.
Trademark Notice. Mounjaro, Zepbound, and Trulicity are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, Rybelsus, Saxenda, and Victoza are registered trademarks of Novo Nordisk A/S. Byetta and Bydureon are registered trademarks of AstraZeneca. FormBlends has no affiliation with Eli Lilly, Novo Nordisk, AstraZeneca, or any other manufacturer of these products.